The FDA approved the use of isatuximab-irfc in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of certain adults with multiple myeloma who are not eligible for stem cell transplantation. This approval was based on results from a phase 3 trial showing a significant reduction in disease progression and death with isatuximab-irfc. Common side effects of this treatment include upper respiratory tract infection, diarrhea, fatigue, and peripheral sensory neuropathy. The recommended IV dose of isatuximab-irfc is 10 mg/kg.
Source link
FDA approves isatuximab-irfc combination for certain adults with multiple myeloma
